Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Bank of England fines Vocalink £11.9m for compliance failure

(Sharecast News) - The Bank of England announced on Wednesday that it has fined Mastercard-backed payment systems company Vocalink for £11.9m, marking the first time the central bank has fined a financial market infrastructure firm. The fine relates to a compliance failure under section 196 of the Banking Act 2009, after the company failed to adequately remediate "a number of identified systems and controls issues" highlighted by the BoE.

The central bank, which has regulated Vocalink since 2018 given its position as a financial market infrastructure firm involved in the operation of UK payments systems, had given the company a deadline in February 2022 to comply with its requirements.

However, the Bank said Vocalink "failed to comply in full" with its requirements in time, blaming an "ineffective risk management framework, combined with weaknesses in its controls, governance arrangements and escalation processes".

Had the company not co-operated throughout the BoE's investigation, including the early admission of a compliance failure, and not been willing to resolve the matter, the fine imposed by the central bank would have been £20m.

In a statement, Sarah Breeden, deputy governor for financial stability at the BoE, said Vocalink "fell short of its obligation" to have appropriate risk management and governance processes in place.

"The Bank's investigation identified the root cause of Vocalink's non-compliance was the failure to have in place a sufficiently integrated risk management framework for the remediation programme. This would have ensured that risks facing the programme could be properly understood, monitored and shared amongst the three lines of defence (and external assurance providers)," the Bank said.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.